Table 1.
Clinical and demographic characteristics of RA patients and healthy controls.
| Characteristic | Healthy controls | RA | p |
|---|---|---|---|
| Number of subjects | 50 | 50 | P = 1 |
| Age (year) | 52 ± 5 | 57.87 ± 11.85 | P > 0.05 |
| Female/male ratio | 20:30 | 43:7 | P < 0.01 |
| BAFF (pg/mL) | 1920 ± 91 | 2700 ± 241 | P < 0.01 |
| ESR (mm/h) | 15.21 ± 4.28 | 40.67 ± 34.28 | P < 0.01 |
| CRP (mg/L) | 6.39 ± 4.31 | 46.69 ± 26.31 | P < 0.01 |
| RF (IU/mL) | 13.23 ± 11.11 | 138.99 ± 113.11 | P < 0.01 |
| Anti-CCP (IU/mL) | 8.14 ± 6.35 | 581.14 ± 489.39 | P < 0.01 |
| Scores of joints | – | 3.38 ± 1.86 | – |
| Scores of X-ray | – | 2.71 ± 1.20 | – |
| Pain (VAS) | – | 3.36 ± 1.17 | – |
| PGA (VAS) | – | 4.69 ± 2.58 | – |
| EGA (VAS) | – | 3.56 ± 2.32 | – |
| HAQ | – | 0.77 ± 0.36 | – |
| DAS28 | – | 4.01 ± 1.83 | – |
Anti-CCP anti-cyclic citrullinated peptide, BAFF B cell activating factor of TNF family, CRP C-reactive protein, DAS28 disease activity score in 28 joints, EGA evaluator global assessment of disease activity, ESR erythrocyte sedimentation rate, HAQ health assessment questionnaire, PGA patient’s global assessment of disease activity, RF rheumatoid factor, VAS visual analogue scale.